Stephen J. Kolb, MD, PhD is the Director of The Ohio State University Wexner Medical Center ALS/MND Multidisciplinary Clinic and Research Program and a Professor of Neurology and Biological Chemistry & Pharmacology at OSUWMC. Dr. Kolb earned an MD and PhD in Neurosciences at the University of Texas Health Science Center in Houston. He completed neurology residency at the Hospital of the University of Pennsylvania and postdoctoral fellowship at Penn in the laboratory of Gideon Dreyfuss, Ph.D. The Kolb Lab is focused on understanding the molecular basis of cell selectivity in motor neuron diseases and has developed novel patient-derived, cell-based and animal models of hereditary axonal neuropathy, spinal muscular atrophy and ALS. A physician-scientist, he also initiated and led the inaugural clinical study of the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) that defined the natural history of infantile-onset SMA and hastened the development of disease modifying gene therapies in SMA. He and his Team at The Ohio State University are currently focused on the development and clinical delivery of targeted gene therapies to individuals with ALS.